ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 1

Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

, , , ,

This episode explores expert insights on the clinical use of osimertinib in the frontline setting for EGFR-mutated NSCLC, the impact of combining osimertinib with platinum-based chemotherapy on progression-free survival (PFS), and the significance of extending PFS by nearly 9 months in patients with advanced NSCLC who are not candidates for curative treatment.

Now Viewing
EP. 1: Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC
EP. 2: Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA
EP. 3: ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC
EP. 4: Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations
EP. 5: Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC
EP. 6: Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges
EP. 7: Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01
EP. 8: Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies
EP. 9: Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC
EP. 10: Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC
EP. 11: Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd
EP. 12: Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

Video content above is prompted by the following:

  • What has been your clinical experience with osimertinib in the frontline setting for EGFR-mutated NSCLC?

  • Please assess the impact of a 38% improvement in PFS with the combination of osimertinib and platinum-based chemotherapy vs osimertinib monotherapy in patients with advanced EGFR-mutated NSCLC.

  • From the perspective of a community oncologist, please share your insights on the meaningful benefit of extending PFS an additional 8.8-9.5 months among untreated patients with advanced NSCLC, not amenable to curative resection or radiotherapy.